Microdosing is a commercial term before it is a clinical one. A seller using it means a plan that holds you well below the maintenance dose the labels describe, and prices that plan under its standard one. Someone weighing a low figure against a standard figure is really being asked whether less drug for less money is a good trade — which is a fair question, and the price boards cannot answer it on their own.
The word carries no quantity
There is no agreed definition and no labeled dose called a microdose. In practice the term covers at least three different things: staying at the starting dose indefinitely instead of climbing, taking a fraction of the starting dose, or stretching the same amount over a longer interval between doses.
Those are not interchangeable, and two plans advertised with the same word can differ severalfold in how much drug you actually receive. So the first move is not to compare prices at all. It is to get the milligrams per dose, the dosing interval and the concentration of the vial in writing, because without those three numbers the price is attached to an unknown quantity. That is the same standard any published figure here has to meet before it reaches a board.
The one trial that measured lower doses
Lower doses of semaglutide have been studied. A phase 2 dose-ranging trial randomized 957 adults with obesity to daily subcutaneous semaglutide at 0.05, 0.1, 0.2, 0.3 or 0.4 mg, to liraglutide, or to placebo, for 52 weeks. Estimated mean weight loss ran −6.0%, −8.6%, −11.6%, −11.2% and −13.8% across those doses, against −2.3% on placebo.[1]
That result deserves reading in both directions. The smallest dose tested amounts to 0.35 mg of semaglutide a week, a fraction of the 2.4 mg weekly maintenance dose, and it still beat placebo by almost four percentage points. Anyone claiming a small dose does nothing is arguing against the data.
The same table points the other way just as clearly. The smallest dose produced under half the reduction of the largest one in the same trial, with the same participants and the same measurement. More drug produced more weight loss, and the relationship was steep through the bottom of the range.
The other molecule behaves the same way where it has been tested. In SURMOUNT-1 each of the three tirzepatide doses was carried as a separate randomized arm, and the mean reduction rose with every step up the ladder.[2] Dose-response is not in dispute for either drug. What is missing is any arm that resembles what is being sold.
Why that is still not a trial of microdosing
Three differences matter. The trial gave daily subcutaneous injections, not a reduced weekly schedule. Each group was assigned a target dose and held there, rather than being kept low because of cost or preference. And it used the branded molecule at a known concentration, supplied and measured under trial conditions.
A plan sold as a microdose is usually none of those things. It is a compounded preparation, weekly, at a concentration the buyer is often not told, on a schedule chosen commercially. The dose-response evidence tells you the shape of the curve for the molecule. It does not tell you where on that curve a particular seller’s plan places you, and neither does the price.
The pivotal weight-loss trials do not close the gap either. They tested labeled maintenance doses in people who had climbed to them, which is a different question entirely, and their results describe the branded products rather than what a pharmacy prepares to order.
Comparing a low price against a standard one
The central point is that these two prices do not buy the same thing. A lower monthly figure for a lower dose is a smaller purchase, not a discount, and the arithmetic that makes two sellers comparable is cost per month at the dose you expect to be taking in month six.
That is where the second cost usually hides. A plan that opens at a low dose and re-prices at every step upward can end the year above a plan that looked expensive on day one. Sellers that hold one price across every dose remove that variable, and a plan advertised as a microdose is worth checking on exactly this point before the first charge.
Reasons a lower dose can still be right
Plenty of people take a reduced dose for sound reasons, and the evidence gap is not an argument against any of them. Some cannot tolerate the labeled maintenance dose; a dose someone stays on beats a dose they abandon in week six, which is the practical lesson of the side-effect data. Some reach a weight they are content with before the top of the schedule. Some have a prescriber who set the dose deliberately.
None of that is what the marketing word is doing, though. A prescriber holding you at 0.5 mg because of nausea has made a clinical judgment. A plan named for its price tier has made a commercial one, and the two only look alike from outside.
What nobody can tell you yet
Whether a reduced dose protects the result over time is unstudied, and it is the question that decides the real cost. Weight regain after stopping has been measured directly for both molecules at full doses — see the withdrawal trials — and no equivalent work covers a maintained low dose. If a seller implies otherwise, that is a claim with nothing behind it. Where a plan is heading and what it will cost at each rung is the checkable part, and the seller write-ups record what each one publishes.